764 related articles for article (PubMed ID: 10696733)
21. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations.
Schrag D; Kuntz KM; Garber JE; Weeks JC
JAMA; 2000 Feb; 283(5):617-24. PubMed ID: 10665701
[TBL] [Abstract][Full Text] [Related]
22. BRCA1 and BRCA2 mutation carriers as potential candidates for chemoprevention trials.
Levy-Lahad E; Krieger M; Gottfeld O; Renbaum P; Klein G; Eisenberg S; Lahad A; Kaufman B; Catane R
J Cell Biochem Suppl; 2000; 34():13-8. PubMed ID: 10762009
[TBL] [Abstract][Full Text] [Related]
23. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K
N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992
[TBL] [Abstract][Full Text] [Related]
24. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome.
Roukos DH; Briasoulis E
Nat Clin Pract Oncol; 2007 Oct; 4(10):578-90. PubMed ID: 17898808
[TBL] [Abstract][Full Text] [Related]
25. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
Metcalfe KA; Lubinski J; Ghadirian P; Lynch H; Kim-Sing C; Friedman E; Foulkes WD; Domchek S; Ainsworth P; Isaacs C; Tung N; Gronwald J; Cummings S; Wagner T; Manoukian S; Møller P; Weitzel J; Sun P; Narod SA;
J Clin Oncol; 2008 Mar; 26(7):1093-7. PubMed ID: 18195327
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.
Anderson K; Jacobson JS; Heitjan DF; Zivin JG; Hershman D; Neugut AI; Grann VR
Ann Intern Med; 2006 Mar; 144(6):397-406. PubMed ID: 16549852
[TBL] [Abstract][Full Text] [Related]
27. Reducing the risk of breast cancer with tamoxifen in women at increased risk.
Vogel VG
J Clin Oncol; 2001 Sep; 19(18 Suppl):87S-92S. PubMed ID: 11560980
[TBL] [Abstract][Full Text] [Related]
28. Chemoprevention: drug pricing and mortality: the case of tamoxifen.
Melnikow J; Kuenneth C; Helms LJ; Barnato A; Kuppermann M; Birch S; Nuovo J
Cancer; 2006 Sep; 107(5):950-8. PubMed ID: 16865680
[TBL] [Abstract][Full Text] [Related]
29. [Chemoprevention and prophylactic surgery in ovarian carcinoma].
Deffieux X; Touboul C; Uzan C; Faivre E; Frydman R; Fernandez H; Morice P
J Gynecol Obstet Biol Reprod (Paris); 2007 Dec; 36(8):756-63. PubMed ID: 17719183
[TBL] [Abstract][Full Text] [Related]
30. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
[TBL] [Abstract][Full Text] [Related]
31. [Prophylactic mastectomy in women at high risk for breast and ovarian cancer: qualitative analysis of the decision making process and long-term satisfaction of two women carrying a BRCA1-mutation].
Vodermaier A; Bauerfeind I; Untch M; Nestle-Krämling C
Psychother Psychosom Med Psychol; 2006; 56(9-10):351-61. PubMed ID: 16804803
[TBL] [Abstract][Full Text] [Related]
32. [Genetic test and prophylactic treatment in breast cancer families].
Miyoshi Y; Noguchi S
Gan To Kagaku Ryoho; 2002 Apr; 29(4):512-22. PubMed ID: 11977534
[TBL] [Abstract][Full Text] [Related]
33. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation.
Modan B; Hartge P; Hirsh-Yechezkel G; Chetrit A; Lubin F; Beller U; Ben-Baruch G; Fishman A; Menczer J; Struewing JP; Tucker MA; Wacholder S;
N Engl J Med; 2001 Jul; 345(4):235-40. PubMed ID: 11474660
[TBL] [Abstract][Full Text] [Related]
34. Factors associated with decisions about clinical BRCA1/2 testing.
Armstrong K; Calzone K; Stopfer J; Fitzgerald G; Coyne J; Weber B
Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1251-4. PubMed ID: 11097234
[TBL] [Abstract][Full Text] [Related]
35. Radiation therapy plus tamoxifen versus tamoxifen alone after breast-conserving surgery in postmenopausal women with stage I breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Lee JH; Recht A
J Clin Oncol; 2003 Jun; 21(12):2260-7. PubMed ID: 12805324
[TBL] [Abstract][Full Text] [Related]
36. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.
Friebel TM; Domchek SM; Neuhausen SL; Wagner T; Evans DG; Isaacs C; Garber JE; Daly MB; Eeles R; Matloff E; Tomlinson G; Lynch HT; Tung N; Blum JL; Weitzel J; Rubinstein WS; Ganz PA; Couch F; Rebbeck TR
Clin Breast Cancer; 2007 Dec; 7(11):875-82. PubMed ID: 18269778
[TBL] [Abstract][Full Text] [Related]
37. Psychosocial issues following a positive result of genetic testing for BRCA1 and BRCA2 mutations: findings from a focus group and a needs-assessment survey.
Di Prospero LS; Seminsky M; Honeyford J; Doan B; Franssen E; Meschino W; Chart P; Warner E
CMAJ; 2001 Apr; 164(7):1005-9. PubMed ID: 11314429
[TBL] [Abstract][Full Text] [Related]
38. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers.
Metcalfe KA; Lynch HT; Ghadirian P; Tung N; Olivotto IA; Foulkes WD; Warner E; Olopade O; Eisen A; Weber B; McLennan J; Sun P; Narod SA
Gynecol Oncol; 2005 Jan; 96(1):222-6. PubMed ID: 15589605
[TBL] [Abstract][Full Text] [Related]
39. Breast and ovarian cancer genetics and prevention.
Altaha R; Reed E; Abraham J
W V Med J; 2003; 99(5):187-91. PubMed ID: 14959510
[TBL] [Abstract][Full Text] [Related]
40. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Hillner BE
Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]